Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Rhea-AI Summary
Virax Biolabs (NASDAQ: VRAX) signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its research-use-only ImmuneSelect immune profiling line.
The deal covers six Southeast Asian markets, enables immediate purchase-order-based supply, targets tuberculosis-related research in Thailand first, and allows phased regional expansion and OEM/private-label opportunities.
Positive
- Exclusive ImmuneSelect supply deal across six Southeast Asian markets
- Immediate purchase-order-driven commercial execution for ImmuneSelect products
- Access to Fosun Diagnostics’ established ASEAN commercial infrastructure
- Framework for higher-volume supply and OEM/private-label arrangements
- Near-term commercial opportunity separate from ViraxImmune diagnostic platform
Negative
- None.
Market reaction after ImmuneSelect ASEAN supply partnership: VRAX +100.00% in the Jul 9 session
In the Jul 9 session, VRAX gained 100.00%, reflecting a significant positive market reaction. Argus tracked a peak move of +280.4% during that session. Our momentum scanner triggered 185 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 378.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 24 | Share consolidation | Negative | -14.8% | 1-for-25 share consolidation to regain Nasdaq minimum bid price compliance. |
| May 26 | Clinical data update | Positive | -18.2% | Positive early ViraxImmune pilot data for Long COVID and PAIS indications. |
| Apr 14 | Strategy update | Positive | -11.1% | CEO letter outlining ViraxImmune strategy and cash versus market cap context. |
| Mar 31 | ISO certifications | Positive | +35.3% | Quality system ISO certifications supporting regulated IVD development and validation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced sharp but mixed moves, with several positive updates met by negative price reactions.
Key Terms
research-use-only technical
ruo technical
elispot medical
oem technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ImmuneSelect is Virax's commercially available research-use-only ("RUO") immune profiling product line and is distinct from ViraxImmune™, the Company's in-development diagnostic platform currently progressing through clinical and regulatory development.
Virax believes the agreement represents a significant commercial milestone for its ImmuneSelect platform, providing access to multiple Southeast Asian markets through a leading regional diagnostics organization. The framework is designed to support phased commercial expansion, including additional product offerings, higher-volume supply arrangements, and potential OEM or private-label arrangements.
Fosun Diagnostics is the core entity of the diagnostics business under Fosun Medtech, a division of Fosun Pharma. Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group with operations spanning pharmaceuticals, medical technologies, diagnostics and healthcare services. Fosun Pharma reported 2025 revenue of
KEY HIGHLIGHTS:
- Commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets, with exclusivity subject to agreed minimum purchase and performance requirements.
- Supports near-term potential revenue opportunities through purchase-order-driven supply of Virax's commercially available ImmuneSelect product line.
- Provides access to Fosun Diagnostics' established regional commercial infrastructure and customer network.
- Framework supports expansion into additional products, higher-volume supply arrangements and potential OEM/private-label opportunities.
- Near-term commercial opportunity separate from ViraxImmune™, the Company's in-development diagnostic platform.
Virax will supply ImmuneSelect immune profiling products, including ELISpot assay plates used to measure cellular immune responses, to Fosun Diagnostics under purchase orders, enabling immediate commercial execution. Pricing includes structured volume-based tiers reflecting scalable commercial economics across the ASEAN region. The initial focus is tuberculosis-related research applications in
"This agreement represents a major step forward in the commercial rollout of our ImmuneSelect platform across
"We are pleased to collaborate with Virax Biolabs as we evaluate ELISpot-based research applications across
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction. Its principal programs are ViraxImmune™, an in-development T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents.
For more information, please visit www.viraxbiolabs.com
About Fosun Diagnostics
Founded in 1989, Fosun Diagnostics is an in vitro diagnostics company focused on the development and implementation of innovative diagnostic technologies and products. Fosun Diagnostics is the core entity of the diagnostics business under Fosun Medtech, a division of Fosun Pharma, with six major R&D and production bases across China. Fosun Pharma is an innovation-driven global pharmaceutical and healthcare group listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, with businesses across pharmaceuticals, medical technologies, diagnostics and healthcare services.
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.
In evaluating these forward-looking statements, you should consider various factors, including: our ability to keep pace with new technology and changing market needs; the possibility that the supply agreement with Fosun Diagnostics may not generate anticipated revenue or achieve expected commercial results; potential for clinical, analytical or performance studies to generate statistically and/or clinically meaningful evidence sufficient to support regulatory submissions, commercialization or adoption, failure of preliminary, interim or top-line data to accurately reflect the complete results of a trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA and other regulators' agreement on the regulatory path for ViraxImmune™ or other potential products; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.
These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2026. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-signs-multi-country-commercial-supply-agreement-with-fosun-diagnostics-302820805.html
SOURCE Virax BioLabs Group Limited